Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Aug 18;10(8):1212-1216.
doi: 10.18240/ijo.2017.08.04. eCollection 2017.

Inhibitory effect of tenomodulin versus ranibizumab on in vitro angiogenesis

Wei Wang  1 , Guang-Xu Liu  2 , Yue-Hua Li  1 , Xue-Dong Li  1 , Yan He  2
Affiliations

Inhibitory effect of tenomodulin versus ranibizumab on in vitro angiogenesis

Wei Wang et al. Int J Ophthalmol. .

Abstract

Aim: To evaluate anti-angiogenic effect of tenomodulin (TNMD) and ranibizumab on cell proliferation and capillary-like morphogenesis of vascular endothelial cells under the stimulation of vascular endothelial growth factor (VEGF) in vitro.

Methods: The effects of TNMD and ranibizumab on VEGF-induced proliferation of human umbilical vein endothelial cells (HUVECs) were evaluated by MTT assay, and the effects of TNMD and ranibizumab on capillary-like structures formed by HUVECs under the stimulation of VEGF were examined in culture. Capillary-like morphogenesis of HUVECs was quantitatively evaluated, and total lengths of tube-like structures per field were measured in a masked way.

Results: HUVECs with both ranibizumab and TNMD protein showed MTT reduction in VEGF-stimulated cell proliferation as expected, while MTT absorbance in the HUVECs with TNMD was significantly declined than that with ranibizumab (P<0.01). The capillary-like structures formed by HUVECs were markedly impaired by the presence of both TNMD and ranibizumab in the culture medium. The total length of the capillary-like structures per field was significantly shorter in the medium with TNMD than that of ranibizumab (P<0.01). The inhibitory effect of TNMD on tube formation in vitro angiogenesis was significantly stronger than that of ranibizumab.

Conclusion: TNMD may have stronger inhibitory effect than ranibizumab on in vitro angiogenesis.

Keywords: angiogenesis; inhibitory effect; proliferation; ranibizumab; tenomodulin.

PubMed Disclaimer

Figures

Figure 1
Figure 1. VEGF screened for optimum concentration of cell proliferation.
Figure 2
Figure 2. Inhibitory effect of TNMD and lucentis on VEGF-induced endothelial proliferation
The suppressive effect of TNMD and lucentis on VEGF-induced endothelial proliferation was evaluated by measurement of MTT assay.
Figure 3
Figure 3. Suppressive effect of TNMD/lucentis on VEGF-induced endothelial proliferation and on in vitro angiogenesis (×100)
The tube morphogenesis of HUVECs in different conditioned culture medium. A: 1% FBS containing medium as positive control; B: Medium including 1% FBS and 100 ng/mL VEGF; C: Medium including 1% FBS, 100 ng/mL VEGF and lucentis 1 µg/mL; D: Medium including 1% FBS, 100 ng/mL VEGF and TNMD 10 µg/mL. Bar chart: quantitative assessment of the length of the capillary structures by image computer analysis. Data are means±SD of three independent experiments. The total length of HUVECs incubated in the medium containing TNMD had significant differences with that of in the other three different conditioned culture medium (P<0.01).
See this image and copyright information in PMC

References

    1. Berg K, Pedersen TR, Sandvik L, Bragadottir R. Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to the LUCAS treat-and-extend protocol. Ophthalmology. 2015;122(1):146–152. - PubMed
    1. Solomon SD, Lindsley K, Vedula SS, Krzystolik MG, Hawkins BS. Anti-vascular endothelial growth factor for neovascular age-related macular degeneration. Cochrane Database Syst Rev. 2014;8:CD005139. - PMC - PubMed
    1. Solomon SD, Lindsley KB, Krzystolik MG, Vedula SS, Hawkins BS. Intravitreal bevacizumab versus ranibizumab for treatment of neovascular age-related macular degeneration. Ophthalmology. 2016;123(1):70–77.e1. - PMC - PubMed
    1. Moja L, Lucenteforte E, Kwag KH, et al. Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration. Cochrane Database Syst Rev. 2014;9:CD011230. - PMC - PubMed
    1. Barquet LA. Role of VEGF in diseases of the retina. Arch Soc Esp Oftalmol. 2015;90(Suppl 1):3–5. - PubMed

LinkOut - more resources